טוען...
Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias
There is no standard or widely effective treatment of patients with moderate aplastic anemia (MAA) or hypo-productive uni-lineage cytopenias (UC). Eltrombopag (EPAG), a small molecule thrombopoietin mimetic, has previously been shown to result in durable multi-lineage hematologic responses with low...
שמור ב:
| הוצא לאור ב: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7189303/ https://ncbi.nlm.nih.gov/pubmed/32330244 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001657 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|